Symphogen, a company which manufactures target-specific recombinant antibodies, has appointed Martin Olin as chief financial officer (CFO). Olin joins from Scandinavia Life Science Invest (SLS Invest), where since 2000 he has been senior investment director and a senior partner of the evergreen investment company focused on supporting small and medium-sized life science companies.
Prior to his position with SLS Invest, Olin was with Novo Nordisk, most recently as the finance director, Europe, Middle East and Africa (EMEA), managing finance, IT, and customer service for the region. Olin has more than a decade of executive experience with life science companies and has been involved in numerous private equity transactions, trade sales and commercial partnerships. He currently serves as a director on the board of several life science companies in the US and Europe. Olin has an Executive MBA from the Scandinavian International Management Institute, and an HA and MSc from the Copenhagen Business School.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.